Survival

The Future of Insurance Europe 2023 First Speakers Announced

Retrieved on: 
Tuesday, May 30, 2023
Insurance, Reuters, AXA, Survival, Head, Innovation, Digital transformation, Growth, XL, AI, System, Ergo Group, Clothing, Cassette tape

London, United Kingdom--(Newsfile Corp. - May 30, 2023) - The world has been turned on its head.

Key Points: 
  • London, United Kingdom--(Newsfile Corp. - May 30, 2023) - The world has been turned on its head.
  • Instead of slowing down, this is the time to come together and capitalise on the unprecedented level of change surrounding us.
  • That's why Reuters Events are inviting you to The Future of Insurance Europe 2023, Europe's most senior insurance event with 350+ decision makers, taking place 28th-29th November, Hotel Novotel Amsterdam City.
  • #FOIEurope 2023 is the meeting point for forward-thinking leaders to find all three - this is your business case to attend!

EQS-News: Mainz Biomed Expands Commercial Footprint into Poland

Retrieved on: 
Thursday, June 1, 2023
Partnership, CRC, Survival, Cancer, Incidence, Patient, Colorectal cancer, Colonoscopy, Pharmaceutical industry

BERKELEY, US – MAINZ, Germany – May 31, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the establishment of a commercial partnership for ColoAlert® with TESTDNA Sp.

Key Points: 
  • BERKELEY, US – MAINZ, Germany – May 31, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the establishment of a commercial partnership for ColoAlert® with TESTDNA Sp.
  • “Entering the Polish market is an important milestone for the Company and we are thrilled by the opportunity to partner with TESTDNA to establish ColoAlert’s commerical footprint in this territory,” commented Darin Leigh, Chief Commercial Officer of Mainz Biomed.
  • Mainz Biomed is providing ColoAlert to TESTDNA under the standard terms of the Company’s partnership agreements.
  • In the coming weeks, Mainz Biomed will work with TESTDNA to prepare and launch co-marketing activities to ensure successful commercialization in the Polish market.

HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers

Retrieved on: 
Wednesday, May 31, 2023
CPI, Progression-free survival, Neoplasm, LCMV, Survival, RECIST, HPV16, Arenavirus, Head, EDT, Patient, Webcast, Pembrolizumab, ORR, Safety, Disease, Pharmaceutical industry

New data show a 43 percent objective response rate (ORR) with HB-200 in combination with pembrolizumab in checkpoint inhibitor (CPI)-naïve patients, doubling the 19 percent response rate for pembrolizumab alone.

Key Points: 
  • New data show a 43 percent objective response rate (ORR) with HB-200 in combination with pembrolizumab in checkpoint inhibitor (CPI)-naïve patients, doubling the 19 percent response rate for pembrolizumab alone.
  • “Efficacy, immunogenicity and safety data observed in our HB-200 program to-date support our decision to progress to a pivotal trial of HB-200 in combination with pembrolizumab as 1st-line treatment for these patients.
  • Given the limited options for heavily pre-treated patients with recurrent/metastatic HPV16+ head and neck cancers, HOOKIPA continues to evaluate HB-200 as monotherapy among these patients in the ongoing Phase 1/2 trial.
  • Alan Ho, M.D., Ph.D., a study investigator, will also offer commentary on the unmet medical need for patients with head and neck cancer.

Evaxion Announces Business Update and First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 31, 2023
Vaccine, Exercise, DNA, AACR, European Medicines Agency, Survival, Infection, Cancer, CTA, CCL19, Immunotherapy, Messenger, Observational study, Erving Goffman, ASCO, Research and development, Development, Patient, Administration, Melanoma, Koala retrovirus, Research, Safety, Genome, Medical imaging, Pharmaceutical industry

“Evaxion continues to make significant progress towards our mission of advancing AI-powered immunotherapies to save lives,” said Per Norlén, Chief Executive Officer of Evaxion.

Key Points: 
  • “Evaxion continues to make significant progress towards our mission of advancing AI-powered immunotherapies to save lives,” said Per Norlén, Chief Executive Officer of Evaxion.
  • Operating spending for the first quarter of 2023 was offset by the proceeds from issue of shares and exercise of warrants.
  • Research and Development expenses were $3.9 million for the quarter ended March 31, 2023 as compared to $4.8 million for the quarter ended March 31, 2022.
  • General and Administrative expenses were $2.5 million for the quarter ended March 31, 2023 as compared to $1.6 million for the quarter ended March 31, 2022.

Enterome announces sustained positive clinical outcomes with EO2401, its lead OncoMimics™ immunotherapy, in combination therapy in Glioblastoma at ASCO

Retrieved on: 
Wednesday, May 31, 2023
Maintenance, Bevacizumab, GBM, Vaccination, Nivolumab, Inflammation, Edema, Survival, Cancer, German Cancer Research Center, DSM-IV codes, Glioblastoma, ASCO, Service provider, VEGF, American Society of Clinical Oncology, Patient, Data, Memory, Annual general meeting, Immunosuppression, Society, Pharmaceutical industry, Vaccine, MD

Nivolumab is used as an adjuvant to EO2401, to support T cell expansion and tumor infiltration.

Key Points: 
  • Nivolumab is used as an adjuvant to EO2401, to support T cell expansion and tumor infiltration.
  • By itself, nivolumab has no observed clinical effect on GBM tumors.
  • Pierre Belichard, CEO at Enterome said, “We are thrilled with the clinical and immunological data emerging from the ROSALIE trial, which we are presenting at ASCO.
  • EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific CD8+ T cells, correlating with clinical efficacy.

Mainz Biomed Expands Commercial Footprint into Poland

Retrieved on: 
Wednesday, May 31, 2023
Partnership, CRC, Survival, Cancer, Incidence, Patient, Colorectal cancer, Colonoscopy, Pharmaceutical industry

BERKELEY, Calif. and MAINZ, Germany, May 31, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the establishment of a commercial partnership for ColoAlert® with TESTDNA Sp. z o.o. Sp. k. Katowice, Poland, a leading independent laboratory in Poland. ColoAlert is Mainz Biomed’s flagship product, a highly efficacious and easy to use, at-home detection test for colorectal cancer (CRC) currently being commercialized across Europe and in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, May 31, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the establishment of a commercial partnership for ColoAlert® with TESTDNA Sp.
  • “Entering the Polish market is an important milestone for the Company and we are thrilled by the opportunity to partner with TESTDNA to establish ColoAlert’s commercial footprint in this territory,” commented Darin Leigh, Chief Commercial Officer of Mainz Biomed.
  • Mainz Biomed is providing ColoAlert to TESTDNA under the standard terms of the Company’s partnership agreements.
  • In the coming weeks, Mainz Biomed will work with TESTDNA to prepare and launch co-marketing activities to ensure successful commercialization in the Polish market.

Actuate Therapeutics Announces Poster Presentations at the 2023 ASCO Annual Meeting

Retrieved on: 
Tuesday, May 30, 2023
PDAC, Abstract, Survival, Clinical trial, Cancer, Disposable and discretionary income, Actuate, ASCO, Patient, Plasma, Colorectal cancer, Annual general meeting, Therapy, Society, American Society of Clinical Oncology, Pharmaceutical industry

CHICAGO and FORT WORTH, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific collaborators at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2 - 6, 2023, in Chicago, Illinois.

Key Points: 
  • CHICAGO and FORT WORTH, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific collaborators at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2 - 6, 2023, in Chicago, Illinois.
  • The abstracts are currently available on the ASCO meeting website .
  • The posters will be available online at https://actuatetherapeutics.com/news-media/ following the presentations.
  • Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.

Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023

Retrieved on: 
Tuesday, May 30, 2023
Bevacizumab, Partnership, Plus Therapeutics, Survival, Glioblastoma, Dassault Group, ASCO, Medidata Solutions, Convection, Incidence, Synthetic control method, American Society of Clinical Oncology, Patient, CED, Annual general meeting, PSTV, Clutch (eggs), Decompression (diving), Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Pharmaceutical industry

AUSTIN, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that a new analysis from its partner Medidata, a Dassault Systèmes company, was accepted for online publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, in Chicago, Illinois.

Key Points: 
  • The abstract titled, “Clinical characterization of patients with recurrent glioblastoma in trials involving CED and non-CED treatment [#417610],” included data sourced from Medidata’s more than 30,000 clinical trials involving more than nine million de-identified participants.
  • “The purpose of this analysis was to determine whether bevacizumab patients could form an appropriate external control for evaluating overall survival in current and upcoming CED trials,” said Norman LaFrance, M.D., Chief Medical Officer of Plus Therapeutics.
  • “The results of this analysis provide confidence in the use of an external control arm formed from aggregated clinical trial data of patients previously treated with bevacizumab to interpret the results of the ReSPECT-GBM Phase 1/2 trials.
  • Thus far, our clinical outcomes are promising compared to those using an external control.

Alpha Cancer Technologies Presents New Data from ACT-903, an AFP-Maytansine Conjugate, in Online Publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, May 31, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ACT, Alpha-fetoprotein, American Journal of Clinical Oncology, Survival, AFP, Cancer, Immunomodulation, Research, ASCO, Journal, American Society of Clinical Oncology, Patient, Organoid, Annual general meeting, ADC, Neoplasm, Society, Safety, Medical imaging

The ASCO meeting will take place in Chicago from June 2-6, 2023.

Key Points: 
  • The ASCO meeting will take place in Chicago from June 2-6, 2023.
  • Now across multiple tumor models, we have observed high activity in treatment groups including statistically significant dose-dependent reduction in tumor volume and increased survival.
  • The research used an ovarian xenograft model compared to control with four dosing regimens of the AFP-maytansine conjugate, ACT-903.
  • ACT plans to submit an Investigational New Drug (IND) application for ACT-903 in 2024.

Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting

Retrieved on: 
Wednesday, May 31, 2023
Health Technology, Health, Oncology, Medical Devices, FGFR, DNA, Nucleic acid thermodynamics, HER2, ESR1, HRD, Survival, Tiffany, Mutation, TKI, Research, ERBB2, NSCLC, GH, ASCO, Helmy Eltoukhy, DNA repair, Patient, Manhattan Center, Annual general meeting, Neoplasm, FDA, Tumor microenvironment, Society, American Society of Clinical Oncology, Safety, Breast cancer, Medical imaging, Vaccine

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data from 17 studies that highlight the contribution of Guardant blood tests and real-world data to advances in precision oncology and cancer screening at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data from 17 studies that highlight the contribution of Guardant blood tests and real-world data to advances in precision oncology and cancer screening at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago.
  • “We look forward to sharing new data at ASCO that demonstrate scientific and clinical advances across the entire continuum of cancer care,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.
  • (Abstract 556, Sunday, June 4, 8-11am, Hall A)
    Guardant Health collaborators will present a session on the ESR1 mutational landscape and the impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.
  • The study also explores additional co-mutations ascertained through broad genomic liquid profiling and their impact on patient survival.